Clinical Trial Update: Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) [Phase 2]

View source ↗

Summary

The Phase 2 HIV vaccine study V520-023 was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• Human Immunodeficiency Virus Infection

Drugs mentioned

• V520

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: AIDS, HIV Infections | Phase 2 | Status: TERMINATED | Results posted: 2011-08-15